dabigatran has been researched along with Obesity in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Celestino Sobral Filho, D; de Barros Guimarães, AA; do Rego Barros, MC; Lima Filho, AIN | 1 |
| Bansal, A; Eisele, CD; Jain, R; Julian, K; Mausteller, KG; Patel, P | 1 |
| Bindler, RJ; Caverley, ZR; Mendelson, S; Soh, P | 1 |
| Akerman, M; Chin-Hon, J; Davenport, L; Hindenburg, A; Huang, J | 1 |
| Branam, DL; Covert, K | 1 |
| Akutsu, D; Maruo, K; Matsui, H; Mizokami, Y; Narasaka, T; Suzuki, H; Tajima, H; Yamasaki, H | 1 |
| Ashton, V; Berger, JS; Jung, Y; Kharat, A; Laliberté, F; Lefebvre, P; Lejeune, D; Moore, KT | 1 |
| Alatawi, Y; Alghamdi, BS; Alshehri, FS; Balabagno, AO; Chen, Y; Durmanova, V; Evangelista, LS; Hromadka, T; Javor, J; Ji, Q; Jiao, J; Kralova, M; Kurdi, M; Labban, S; Li, X; Li, Y; Lv, Q; Minarik, G; Ocenasova, A; Pagsibigan, JS; Parnicka, Z; Reznakova, V; Shawkatova, I; Shen, ZJ; Tian, X; Tu, S; Tuazon, JA; Vaseckova, B; Wang, XY; Wang, Z; Xue, Y; Zeng, LX; Zhang, S; Zhang, ZH; Zuo, C | 1 |
| Atripaldi, U; Bottino, R; Cattaneo, D; Clementi, E; Giannetti, L; Laezza, N; Russo, V | 1 |
| Abrahams, SR; Divanovic, S; Flick, MJ; Goss, A; Kopec, AK; Luyendyk, JP; Mackman, N; Mullins, ES; Owens, AP; Palumbo, JS; Thornton, S; van Ryn, J; Weiler, H | 1 |
| Berrazueta Fernández, JR; de Tapia Majado, B; Sanlés González, I | 1 |
| Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L | 1 |
| Hart, A; Shroff, GR; Stoecker, R | 1 |
| Biehle, L; Trierweiler, D | 1 |
| Dalmau, FG | 1 |
| Breuer, L; Köhrmann, M; Ringwald, J; Schwab, S | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Ge, D; Morrill, AM; Willett, KC | 1 |
| Hansrani, V; Khanbhai, M; McCollum, C | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H | 1 |
8 review(s) available for dabigatran and Obesity
| Article | Year |
|---|---|
Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Body Mass Index; Body Weight; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Vitamin K | 2022 |
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
Topics: Anticoagulants; Body Weight; Dabigatran; Drug Dosage Calculations; Factor Xa Inhibitors; Humans; Obesity; Overweight; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism | 2020 |
Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cyclophosphamide; Dabigatran; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension; Male; Multimorbidity; Obesity; Prognosis; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Assessment; Rivaroxaban; Thromboembolism | 2018 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Dosing of Target-Specific Oral Anticoagulants in Special Populations.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2015 |
The Prevention of Venous Thromboembolism in Surgical Patients.
Topics: Age Factors; Anticoagulants; Communicable Diseases; Dabigatran; Dehydration; Fondaparinux; Heparin, Low-Molecular-Weight; Hormone Replacement Therapy; Humans; Neoplasms; Obesity; Polysaccharides; Primary Prevention; Pulmonary Embolism; Risk Factors; Surgical Procedures, Operative; Venous Thromboembolism; Venous Thrombosis | 2017 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
1 trial(s) available for dabigatran and Obesity
| Article | Year |
|---|---|
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K | 2018 |
12 other study(ies) available for dabigatran and Obesity
| Article | Year |
|---|---|
Obesity Paradox in Atrial Fibrillation and its Relation with the New Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Obesity; Pyridones; Rivaroxaban; Stroke; Thrombin | 2022 |
Direct oral anticoagulants and warfarin safety in rural patients with obesity.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Retrospective Studies; Rural Population; Stroke; Warfarin | 2023 |
Safety and efficacy of oral anticoagulants in extreme weights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Thinness; Venous Thromboembolism; Warfarin | 2023 |
The Risks of Exfoliative Esophagitis in Patients with Atrial Fibrillation: A retrospective observational study.
Topics: Aged; Antithrombins; Atrial Fibrillation; Body Mass Index; Case-Control Studies; Dabigatran; Esophagitis; Female; Humans; Male; Middle Aged; Obesity; Retrospective Studies; Risk Factors | 2020 |
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population.
Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Obesity; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Warfarin | 2021 |
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Angiotensin II; Animals; Antithrombins; Atrial Fibrillation; Body Mass Index; Catheter Ablation; Cohort Studies; Dabigatran; Dogs; Embolism; Factor Xa Inhibitors; Female; Genotype; Hemorrhage; Humans; Hypertension; Hypertrophy, Left Ventricular; Incidence; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Middle Aged; Norepinephrine; Obesity; Polymorphism, Single Nucleotide; Retrospective Studies; Rivaroxaban; Stroke; Sympathectomy | 2017 |
Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Obesity; Rivaroxaban; Stroke | 2021 |
Thrombin promotes diet-induced obesity through fibrin-driven inflammation.
Topics: Adipose Tissue; Adiposity; Amino Acid Motifs; Animals; Blood Glucose; Body Composition; Body Weight; Coagulants; Dabigatran; Diet, High-Fat; Fatty Liver; Female; Fibrin; Genotype; Homozygote; Inflammation; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Obesity; Thrombin; Weight Gain | 2017 |
Hemorrhagic pleuropericardial effusion secondary to dabigatran.
Topics: Aged, 80 and over; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Obesity; Pericardial Effusion; Pericardial Window Techniques; Pleural Effusion | 2018 |
Use of Rivaroxaban in Obesity Cannot be Applied to Use of Dabigatran.
Topics: Anticoagulants; Bariatric Surgery; Dabigatran; Factor Xa Inhibitors; Humans; Obesity; Rivaroxaban | 2018 |
Ischemic stroke in an obese patient receiving dabigatran.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Middle Aged; Obesity; Proton Pump Inhibitors; Stroke | 2013 |
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Body Mass Index; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2012 |